156 related articles for article (PubMed ID: 22299644)
1. Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.
Said AS; Harding LP; Chrystyn H
Br J Clin Pharmacol; 2012 Sep; 74(3):456-64. PubMed ID: 22299644
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of Beclometasone From Two HFA-BDP Formulations With a Spacer.
Said AS; AbuRuz S; Chrystyn H
Respir Care; 2019 Oct; 64(10):1222-1230. PubMed ID: 31138731
[TBL] [Abstract][Full Text] [Related]
3. Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI.
Singh D; Collarini S; Poli G; Acerbi D; Amadasi A; Rusca A
Br J Clin Pharmacol; 2011 Dec; 72(6):932-9. PubMed ID: 21615456
[TBL] [Abstract][Full Text] [Related]
4. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man.
Daley-Yates PT; Price AC; Sisson JR; Pereira A; Dallow N
Br J Clin Pharmacol; 2001 May; 51(5):400-9. PubMed ID: 11421996
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the bioavailability and systemic effects of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler after single-dose administration in healthy male volunteers.
Poli G; Acerbi D
Respir Med; 2003 Feb; 97 Suppl B():S5-9. PubMed ID: 12593521
[TBL] [Abstract][Full Text] [Related]
6. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination.
Bousquet J; Poli G; Acerbi D; Monno R; Ramael S; Nollevaux F
Clin Pharmacokinet; 2009; 48(6):347-58. PubMed ID: 19650674
[TBL] [Abstract][Full Text] [Related]
7. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children.
Agertoft L; Laulund LW; Harrison LI; Pedersen S
Pediatr Pulmonol; 2003 Mar; 35(3):192-9. PubMed ID: 12567387
[TBL] [Abstract][Full Text] [Related]
8. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients.
De Backer W; Devolder A; Poli G; Acerbi D; Monno R; Herpich C; Sommerer K; Meyer T; Mariotti F
J Aerosol Med Pulm Drug Deliv; 2010 Jun; 23(3):137-48. PubMed ID: 20109122
[TBL] [Abstract][Full Text] [Related]
9. Beclomethasone relative availability of oral versus inhaled beclomethasone dipropionate from an HFA-134A metered dose inhaler.
Soria I; Harrison LI; Machacek JH; Cline AC; Stampone PA
Biopharm Drug Dispos; 1998 Jul; 19(5):297-302. PubMed ID: 9673781
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects.
Small CJ; Gillespie M
J Aerosol Med Pulm Drug Deliv; 2018 Jun; 31(3):182-190. PubMed ID: 28937845
[TBL] [Abstract][Full Text] [Related]
11. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler.
Leach CL; Davidson PJ; Hasselquist BE; Boudreau RJ
J Aerosol Med; 2005; 18(4):379-85. PubMed ID: 16379614
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic profile of beclomethasone dipropionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study.
Ratner PH; Melchior A; Dunbar SA; Tantry SK; Dorinsky PM
Clin Ther; 2012 Jun; 34(6):1422-31. PubMed ID: 22621776
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of sodium cromoglycate to the lung following inhalation, using urinary excretion.
Aswania OA; Corlett SA; Chrystyn H
Br J Clin Pharmacol; 1999 Jun; 47(6):613-8. PubMed ID: 10383538
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of beclomethasone 17-monopropionate from a beclomethasone dipropionate extrafine aerosol in adults with asthma.
Harrison LI; Kurup S; Wagner C; Ekholm BP; Larson JS; Kaiser HB
Eur J Clin Pharmacol; 2002 Jun; 58(3):197-201. PubMed ID: 12107606
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy and safety of beclometasone dipropionate suspension for nebulization and beclometasone dipropionate via a metered-dose inhaler in paediatric patients with moderate to severe exacerbation of asthma.
Bisca N; Cernatescu I; Dragomir D; Iacomi A; Mirceau M; Orascanu D
Respir Med; 2003 Feb; 97 Suppl B():S15-20. PubMed ID: 12593523
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of terbutaline to the lung following inhalation, using urinary excretion.
Abdelrahim ME; Assi KH; Chrystyn H
Br J Clin Pharmacol; 2011 Apr; 71(4):608-10. PubMed ID: 21395654
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic properties of inhaled beclometasone dipropionate delivered via hydrofluoroalkane-containing devices.
Derom E; Pauwels RA
Clin Pharmacokinet; 2005; 44(8):815-36. PubMed ID: 16029067
[TBL] [Abstract][Full Text] [Related]
20. Dose-response for adrenal suppression with hydrofluoroalkane formulations of fluticasone propionate and beclomethasone dipropionate.
Fowler SJ; Orr LC; Wilson AM; Sims EJ; Lipworth BJ
Br J Clin Pharmacol; 2001 Jul; 52(1):93-5. PubMed ID: 11453895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
